Breast Cancer: Lifetime Incidence

One in 8 women in the United States will be diagnosed with breast cancer in her lifetime.1

Cause of Death

An estimated 42,250 men and women died from breast cancer in 2024.1

Estimated Prevalence

In 2024, an estimated 310,720 women and 2,800 men were diagnosed with invasive breast cancer.1

Early Detection

When caught in its earliest, localized stages, the 5-year relative survival rate is 99%.1

A Common Cancer

Aside from skin cancers, breast cancer is the most common cancer in American women. Approximately 30% of all new cancer diagnoses in women are breast cancer.1

Treatments for HR+ Disease

Over 70% of breast cancer tumors are hormone receptor (HR)-positive; endocrine-based therapy is the preferred standard of care for the majority of these patients.2,3

Breast Cancer
HR+/HER2- Disease

Aside from skin cancer, breast cancer is the most common cancer diagnosed in women and the second most common cause of death from cancer among women worldwide.3 The identification of the estrogen receptor (ER) and its role in development of most breast cancers led to the development of endocrine therapies.3 First-line treatment combining endocrine therapy with a CDK4/6 inhibitor is the treatment of choice for many of these HR+/human epidermal growth factor receptor 2 negative (HER2-) patients, though mutations develop in up to 40% of patients – more than 90% of these in response to therapy.3

On this site, we invite you to explore more about breast cancer, specifically the HR+/HER2- type. Our goal is to provide you with a better understanding of how this type of cancer arises, the epidemiology and pathophysiology surrounding the disease, and considerations for assessing biomarkers and selecting treatment. We have also provided a patient toolkit specifically for patients that addresses topics such as living with cancer, frequently asked questions, and caregiver support to help patients better understand this type of cancer. Thank you for visiting!

Clinician Portal
Patient Portal

References

  1. National Breast Cancer Foundation. Breast Cancer Facts & Stats. Last updated August 1, 2024. https://www.nationalbreastcancer.org/breast-cancer-facts/.
  2. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055.
  3. Rugo HS. Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician’s perspective. Clin Adv Hematol Oncol. 2023;21:623-632.

This activity is provided by Med Learning Group.
This activity is supported by an educational grant from Lilly.
Copyright © 2025 Med Learning Group. Built by Divigner. All Rights Reserved.

Pin It on Pinterest

Scroll to Top
Note: This CME program was recorded prior to the American Society of Clinical Oncology (ASCO) 2023 meeting in June 2023. Highlights of data released at ASCO include:

Teclistamab

Longer-term data of the Phase 1/2 MajesTEC-1 study showed a high rate of deep and durable response in triple-class exposed MM patients. At 22 median follow up; complete response or better = 43%; duration of response = 24 months (27 months for ≥CR); median PFS = 12.5 months (20 months for ≥CR); median OS = 21.9 months (not reached for ≥CR).

Adverse event profile for all patients (and grade 3/4) included: infections = 78% (52%); CRS = 72% (0.6%); neutropenia = 72% (65%); anemia = 54% (38%); thrombocytopenia = 42% (22%); and lymphopenia = 35% (33%). ICANS occurred in 3% of patients, all grade 1 or 2.

Reference: van de Donk NWCJ, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(suppl 16):8011. doi:10.1200/JCO.2023.41.16_suppl.8011

Linvoseltamab (investigational)

Two Phase 2 full dose cohorts (50 mg and 200 mg) in the LINKER-MM1 trial were studied to optimize dose selection. Linvoseltamab 200 mg showed better efficacy compared with 50 mg, including in patients with high disease burden. The 200 mg dose had consistent efficacy across high-risk subgroups and induced responses in pts who progressed on 50 mg. The recommended dose for further study is now 200mg.

ORR for 200 mg dose = 71%; CR = 30%; very good partial response = 59%. Median duration of response = not reached. The probability of maintaining response at 6 months was 84% and 79% at 12 months. Treatment-emergent adverse events were reported in 95% of patients (grade 3 or higher = 79%): CRS = 45% (1%); neutropenia = 33%; fatigue = 33%; anemia = 27% (24%). ICANS ≥grade 3 = 2%.

References:

Lee HC, et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41(suppl 16):8006. doi:10.1200/JCO.2023.41.16_suppl.8006

Updated Linvoseltamab (BCMAxCD3) Data from pivotal trial demonstrates early, deep, and durable responses in patients with heavily pre-treated multiple myeloma. News release. Regeneron Pharmaceuticals, Inc; May 25, 2025. Accessed June 15, 2023. https://investor.regeneron.com/news-releases/news-release-details/updated-linvoseltamab-bcmaxcd3-data-pivotal-trial-demonstrates

Elranatamab (investigational)

Pooled data from the MagnetismMM studies were presented. In pts with RRMM and prior exposure to BCMA-directed therapies, elranatamab was efficacious and well tolerated; no new safety signals were observed vs the BCMA-naïve population. ORR = 45.3% (prior anti-BCMA therapy = 41%-53%); median time to OR = 1.9 months; complete response or better = 17.4%; duration of response at 9 months = 72% (prior anti-BCMA therapy = 67.3%-78%); median PFS = 4.8 months; median OS 10-month endpoint not reached, but = 60.1% at 9 months.

Treatment-emergent adverse events in all patients (and grade 3 or higher) included: CRS = 65% (1%); anemia = 59% (47%); neutropenia = 44% (41%); thrombocytopenia = 41% (29%); diarrhea = 34% (0%); lymphopenia = 33% (30%); and ICANS = 6% (2%).

Reference: Nooka AK, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies. J Clin Oncol. 2023;41(16 suppl):8008. doi:10.1200/JCO.2023.41.16_suppl.8008

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers